# A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

> **NCT06731699** · PHASE1 · RECRUITING · sponsor: **Chengdu FenDi Pharmaceutical Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- AML
- NHL

## Interventions

- **DRUG:** FD-001

## Key facts

- **NCT ID:** NCT06731699
- **Lead sponsor:** Chengdu FenDi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2026-01-24
- **Final completion:** 2026-03-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731699, "A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06731699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*